603259 药明康德
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入27,702,002-6.23%40,340,80739,354,77822,902,38516,535,431
减:营业总成本19,967,164-2.08%28,708,59129,800,81118,574,51613,928,304
    其中:营业成本16,440,256-5.20%23,728,80024,677,21714,592,25610,253,276
               财务费用(61,970)-90.52%(338,119)(247,968)84,082519,804
               资产减值损失(20,104)-67.30%(156,509)(175,951)(33,056)(62,642)
公允价值变动收益217,647111.97%(37,809)770,079(93,387)52,271
投资收益(164,810)-135.56%233,849187,9491,356,269606,231
    其中:对联营企业和合营企业的投资收益198,950-485.69%(67,560)(46,271)(117,290)(90,752)
营业利润7,890,869-19.54%11,872,28610,652,2496,037,7253,389,485
利润总额7,854,296-19.71%11,831,99110,618,4766,015,6093,369,376
减:所得税费用1,252,685-23.30%2,131,7311,715,866879,662383,126
净利润6,601,612-18.99%9,700,2608,902,6115,135,9472,986,250
减:非控股权益68,677-4.93%93,51188,89838,79226,015
股东净利润6,532,935-19.11%9,606,7498,813,7135,097,1552,960,235

市场价值指针
每股收益 (元) *2.250-18.18%3.2703.0101.7501.060
每股派息 (元) *----0.9900.8930.5170.363
每股净资产 (元) *18.9479.04%18.57015.73713.02013.308
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容